AdvaMed Calls on CMS to Ensure Access to Essential Medical Equipment

AdvaMed, the leading trade association for medical technology innovators, has issued a statement regarding the U.S. Centers for Medicare & Medicaid Services’ (CMS) recent final rule for the 2026 Home Health Prospective Payment System. The association emphasizes the importance of ensuring access to essential medical equipment, particularly for individuals with diabetes and those dependent on ostomy and urological supplies.

Key Insights from AdvaMed’s Statement

Scott Whitaker, AdvaMed’s President and CEO, expressed support for CMS’s efforts to maintain the Medicare trust fund and lower out-of-pocket costs for patients. He highlighted the need for continuous access to advanced technologies for those managing Type-1 and Type-2 diabetes.

• Patients using Continuous Glucose Monitors (CGMs) experience significantly better health outcomes.
• Poorly managed diabetes can result in severe health complications and increased hospital visits.
• The average cost of a single hypoglycemic episode requiring medical intervention is $1,161.
• CGMs can decrease monthly diabetes-related medical costs by approximately $424 per patient.

Concerns over Competitive Bidding Program

Whitaker raised concerns regarding the competitive bidding program’s impact on patient access to essential supplies. AdvaMed acknowledges CMS’s responsiveness to stakeholder feedback and appreciates the implementation timeline extension and contract expansion. However, the organization insists on the necessity for suppliers to provide diabetes devices prescribed by physicians to ensure patients receive appropriate technologies.

Opposition to Bidding for Ostomy and Urological Supplies

AdvaMed strongly opposes including ostomy and urological supplies in the competitive bidding program. These items, classified as prosthetic devices, are not durable medical equipment and should not fall under CMS’s competitive bidding authority. The association argues that disruptions to access these supplies could lead to severe medical issues and increased healthcare costs.

In an earlier comment letter submitted in August, AdvaMed urged CMS to address specific “serious flaws” in the proposal before proceeding. This month, they welcomed bipartisan support from lawmakers in both the House of Representatives and the Senate, who voiced their concerns regarding reduced patient access to critical diabetes management products.

Conclusion

AdvaMed remains committed to collaborating with CMS to ensure that the Home Health Prospective Payment System supports access to safe and effective medical equipment. As discussions progress, the organization will continue advocating for the needs of patients managing chronic conditions, particularly those requiring diabetes care and specialized medical supplies.